{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:25:00Z","timestamp":1760401500908,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Reducing critically ill patients\u2019 exposure to antibiotics is mandatory. In randomized controlled trials, procalcitonin (PCT)-guided algorithms (i.e., antibiotic therapy [ABT] should be stopped whenever PCT is less than 0.5 \u00b5g\/L or is below 80% of the peak value) reduced the duration of (ABT) more than compliance with the current guidelines. However, the interest of such stopping rules in daily practice remains debated. Thus, we carried out a real-life study addressing this issue. Results: During the study period, 112 patients with sepsis upon intensive care unit admittance were included. The median age was 66 years (56\u201379). Half of the patients presented with acute respiratory failure. Pneumonia was diagnosed in 78% of them, and 41% met septic shock criteria. The initial ABT was empirical in most cases, and appropriateness rate to the isolated bacteria reached 71%. A median number of four PCT measurements was achieved in both groups. The compliance rate with the PCT algorithm was 54%. The median duration of ABT was 5 (4\u20137) days if the PCT algorithm was followed, as compared to 7 (5\u201310) days otherwise (p &lt; 0.001). This ABT stopping rule allowed a 2-day reduction in the treatment duration as compared with those recommended by the guidelines (p &lt; 0.001). The only independent factor associated with shorter treatment duration was compliance with the PCT algorithm (OR = 0.74, 95% CI [0.62; 0.88]; p &lt; 0.001). Regarding safety, no difference in outcome was found between the two groups. Conclusions: Complying with one PCT-based stopping rule is associated with a significant reduction in the duration of ABT in septic critically ill patients, without apparent impact on patient outcomes.<\/jats:p>","DOI":"10.3390\/antibiotics14101012","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:10:31Z","timestamp":1760343031000},"page":"1012","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Complying with a Procalcitonin-Guided Stopping Rule on the Duration of Antibiotic Therapy in Critically Ill Patients: A Real-Life Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-7858","authenticated-orcid":false,"given":"Edwige","family":"P\u00e9ju","sequence":"first","affiliation":[{"name":"Service de M\u00e9decine Intensive-R\u00e9animation, H\u00f4pital F. Mitterrand, CHU Dijon Bourgogne, 14 Rue Paul Gaffarel, B.P. 77908, 21079 Dijon CEDEX, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auguste","family":"Dargent","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Intensive-R\u00e9animation, H\u00f4pital F. Mitterrand, CHU Dijon Bourgogne, 14 Rue Paul Gaffarel, B.P. 77908, 21079 Dijon CEDEX, France"},{"name":"Lipness Team UMR 1231, LabExLipSTIC, Universit\u00e9 Bourgogne Franche-Comt\u00e9, 7 Boulevard Jeanne d\u2019Arc, 21000 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Roudaut","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Intensive-R\u00e9animation, H\u00f4pital F. Mitterrand, CHU Dijon Bourgogne, 14 Rue Paul Gaffarel, B.P. 77908, 21079 Dijon CEDEX, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Prin","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Intensive-R\u00e9animation, H\u00f4pital F. Mitterrand, CHU Dijon Bourgogne, 14 Rue Paul Gaffarel, B.P. 77908, 21079 Dijon CEDEX, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Andreu","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Intensive-R\u00e9animation, H\u00f4pital F. Mitterrand, CHU Dijon Bourgogne, 14 Rue Paul Gaffarel, B.P. 77908, 21079 Dijon CEDEX, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Large","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Intensive-R\u00e9animation, H\u00f4pital F. Mitterrand, CHU Dijon Bourgogne, 14 Rue Paul Gaffarel, B.P. 77908, 21079 Dijon CEDEX, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2351-682X","authenticated-orcid":false,"given":"Jean-Pierre","family":"Quenot","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Intensive-R\u00e9animation, H\u00f4pital F. Mitterrand, CHU Dijon Bourgogne, 14 Rue Paul Gaffarel, B.P. 77908, 21079 Dijon CEDEX, France"},{"name":"Lipness Team UMR 1231, LabExLipSTIC, Universit\u00e9 Bourgogne Franche-Comt\u00e9, 7 Boulevard Jeanne d\u2019Arc, 21000 Dijon, France"},{"name":"INSERM CIC 1432 Epid\u00e9miologie Clinique, Essai Clinique, CHU Dijon Bourgogne, 7 Boulevard Jeanne d\u2019Arc, 21000 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Emmanuel","family":"Charles","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Intensive-R\u00e9animation, H\u00f4pital F. Mitterrand, CHU Dijon Bourgogne, 14 Rue Paul Gaffarel, B.P. 77908, 21079 Dijon CEDEX, France"},{"name":"Lipness Team UMR 1231, LabExLipSTIC, Universit\u00e9 Bourgogne Franche-Comt\u00e9, 7 Boulevard Jeanne d\u2019Arc, 21000 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S2214-109X(18)30186-4","article-title":"Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: Results of an internet-based global point prevalence survey","volume":"6","author":"Versporten","year":"2018","journal-title":"Lancet Glob."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","article-title":"Understanding the mechanisms and drivers of antimicrobial resistance","volume":"387","author":"Holmes","year":"2016","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jiph.2019.07.025","article-title":"Mortality attributable to hospital acquired infections with multidrug-resistant bacteria in a large group of German hospitals","volume":"13","author":"Neubeiser","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.medmal.2017.01.007","article-title":"Proposal for shorter antibiotic therapies","volume":"47","author":"Wintenberger","year":"2017","journal-title":"Med. Mal. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Payne, L.E., Gagnon, D.J., Riker, R.R., Seder, D.B., Glisic, E.K., Morris, J.G., and Fraser, G.L. (2017). Cefepime-induced neurotoxicity: A systematic review. Crit. Care, 21.","DOI":"10.1186\/s13054-017-1856-1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.cmi.2021.10.022","article-title":"Estimating daily antibiotic harms: An umbrella review with individual study meta-analysis","volume":"28","author":"Curran","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/ajrccm.164.3.2009052","article-title":"Diagnostic Value of Procalcitonin, Interleukin-6, and Interleukin-8 in Critically Ill Patients Admitted with Suspected Sepsis","volume":"164","author":"Harbarth","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Charles, P.E., Tinel, C., Barbar, S., Aho, S., Prin, S., Doise, J.M., Olsson, N.O., Blettery, B., and Quenot, J.P. (2009). Procalcitonin kinetics within the first days of sepsis: Relationship with the appropriateness of antibiotic therapy and the outcome. Crit. Care, 13.","DOI":"10.1186\/cc7751"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1164\/rccm.201201-0037OC","article-title":"Combination Biomarkers to Diagnose Sepsis in the Critically Ill Patient","volume":"186","author":"Gibot","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1164\/rccm.200708-1238OC","article-title":"Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial","volume":"177","author":"Nobre","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","article-title":"Use of procalcitonin to reduce patients\u2019 exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial","volume":"375","author":"Bouadma","year":"2010","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial","volume":"16","author":"Beishuizen","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1164\/rccm.200512-1922OC","article-title":"Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial","volume":"174","author":"Stolz","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archinternmed.2012.770","article-title":"Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in \u201creal life\u201d: An international, multicenter poststudy survey (ProREAL)","volume":"172","author":"Albrich","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1473-3099(17)30592-3","article-title":"Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: A patient level meta-analysis","volume":"18","author":"Schuetz","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1183\/09031936.00053209","article-title":"Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: A randomised study","volume":"34","author":"Stolz","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00423-008-0432-1","article-title":"Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: Results of a prospective randomized study. Langenbeck\u2019s","volume":"394","author":"Schroeder","year":"2008","journal-title":"Arch. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hochreiter, M., K\u00f6hler, T., Schweiger, A.M., Keck, F.S., Bein, B., von Spiegel, T., and Schroeder, S. (2009). Procalcitonin to guide duration of antibiotic therapy in intensive care patients: A randomized prospective controlled trial. Crit. Care, 13.","DOI":"10.1186\/cc7903"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201408-1483OC","article-title":"Procalcitonin Algorithm in Critically Ill Adults with Undifferentiated Infection or Suspected Sepsis. A Randomized Controlled Trial","volume":"190","author":"Shehabi","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1097\/CCM.0b013e3181f17bf9","article-title":"Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Kopterides","year":"2010","journal-title":"Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wirz, Y., Meier, M.A., Bouadma, L., Luyt, C.E., Wolff, M., Chastre, J., Tubach, F., Schroeder, S., Nobre, V., and Annane, D. (2018). Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: A patient-level meta-analysis of randomized trials. Crit. Care, 22.","DOI":"10.1186\/s13054-018-2125-7"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa1802670","article-title":"Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection","volume":"379","author":"Huang","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chaitidis, N., Kokkinidis, D.G., Papadopoulou, Z., Kyriazopoulou, M., Schizas, D., and Bakoyiannis, C. (2021). Treatment of chronic venous disorder: A comprehensive review. Dermatol. Ther., 35.","DOI":"10.1111\/dth.15238"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2024.26458","article-title":"Biomarker-Guided Antibiotic Duration for Hospitalized Patients with Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial","volume":"333","author":"Dark","year":"2025","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcrc.2019.05.022","article-title":"Adhering to the procalcitonin algorithm allows antibiotic therapy to be shortened in patients with ventilator-associated pneumonia","volume":"53","author":"Beye","year":"2019","journal-title":"J. Crit. Care"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamainternmed.2013.3029","article-title":"Prolonged antibiotic treatment in long-term care: Role of the prescriber","volume":"173","author":"Daneman","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/2047-783X-16-12-543","article-title":"The use of a standardized PCT-algorithm reduces costs in intensive care in septic patients\u2014A DRG-based simulation model","volume":"16","author":"Wilke","year":"2011","journal-title":"Eur. J. Med. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kip, M.M.A., van Oers, J.A., Shajiei, A., Beishuizen, A., Berghuis, A.M.S., Girbes, A.R., de Jong, E., de Lange, D.W., Nijsten, M.W.N., and IJzerman, M.J. (2018). Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: Results from a randomised controlled multicentre trial in the Netherlands. Crit. Care, 22.","DOI":"10.1186\/s13054-018-2234-3"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jama.2016.0288","article-title":"Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Seymour","year":"2016","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: Results of a multicenter, prospective study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A New Simplified Acute Physiology Score (SAPS II) Based on a European\/North American Multicenter Study","volume":"270","author":"Lemeshow","year":"1993","journal-title":"JAMA"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/10\/1012\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:57:22Z","timestamp":1760345842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/10\/1012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["antibiotics14101012"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14101012","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]}}}